Analysts Have Conflicting Sentiments on These Healthcare Companies: Integra Lifesciences (IART) and Revvity (RVTY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Integra Lifesciences (IART – Research Report) and Revvity (RVTY – Research Report).

Integra Lifesciences (IART)

J.P. Morgan analyst Robbie Marcus maintained a Sell rating on Integra Lifesciences on October 26 and set a price target of $38.00. The company’s shares closed last Monday at $35.06, close to its 52-week low of $33.44.

According to TipRanks.com, Marcus is a 5-star analyst with an average return of 8.4% and a 50.4% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Inspire Medical Systems, and Edwards Lifesciences.

The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Integra Lifesciences with a $41.71 average price target, representing a 20.7% upside. In a report issued on October 25, Citi also maintained a Sell rating on the stock with a $36.00 price target.

See the top stocks recommended by analysts >>

Revvity (RVTY)

In a report released yesterday, Rachel Vatnsdal from J.P. Morgan maintained a Hold rating on Revvity, with a price target of $85.00. The company’s shares closed last Monday at $82.08, close to its 52-week low of $79.50.

According to TipRanks.com, Vatnsdal is a 1-star analyst with an average return of -3.4% and a 28.6% success rate. Vatnsdal covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Akoya Biosciences, and Myriad Genetics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Revvity with a $116.09 average price target, implying a 43.3% upside from current levels. In a report issued on October 20, Bank of America Securities also maintained a Hold rating on the stock with a $128.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IART:

• Integra LifeSciences price target lowered to $39 from $41 at Truist
• Integra LifeSciences price target lowered to $40 from $47 at Wells Fargo
• Integra LifeSciences sees Q4 adjusted EPS 89c-93c, consensus 92c
• Integra LifeSciences narrows FY23 EPS view to $3.10-$3.14 from $3.10-$3.18
• Integra LifeSciences reports Q3 adjusted EPS 76c, consensus 78c